The medicine candidate has been designed for eliciting a targeted T cell response against HPV-6 and HPV-11. Credit: aslysun via Shutterstock.com.

Inovio has received orphan drug designation for INO-3107 from the European Commission (EC) to treat recurrent respiratory papillomatosis (RRP).

The investigational DNA medicine candidate INO-3107 has been designed for eliciting a targeted T cell response against HPV[human papillomavirus]-6 and HPV-11, the types of HPV that cause RRP and other related diseases.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The latest designation comes after the European committee for orphan medicinal products provided a positive opinion on the company’s application for the therapy.

In July 2020, the US Food and Drug Administration (FDA) also granted orphan drug designation to INO-3107.

This makes INO-3107 the first RRP product candidate to receive designations from both the EU and the US regulatory agencies.

Inovio Regulatory Affairs senior vice-president Dr Cheryl Elder stated: “By granting orphan drug designation, US and EU regulators are acknowledging the high unmet medical need of those suffering from this debilitating disease.

“This is yet another important step forward for our development process and for the RRP patients around the world who could benefit from a potentially game-changing therapy.”

The regulatory agency provides orphan status for medicines to qualify for financial and regulatory incentives including access to centralised marketing authorisation, protocol support at reduced charges and market exclusivity for up to 10 years in the EU on obtaining approval.

In 2021, Inovio and the Colombia Ministry of Health and Social Protection signed a non-binding memorandum of understanding to extend efforts to fight the Covid-19 pandemic and future threats.